Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 19/20 | 0.80 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.80 |
| ▸ | MAPK8 | P45983 | 15/20 | 0.80 |
| ▸ | MAPK9 | P45984 | 15/20 | 0.80 |
| ▸ | MAPK10 | P53779 | 15/20 | 0.80 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.56 |
| ▸ | YES1 | P07947 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14506608 | 0.89 | MAPK1 (1.00) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| Hydrochloric Acid SCHEMBL16673960 | 0.88 | MAPK1 (0.98) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14506632 | 0.85 | MAPK1 (1.00) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4340914 | 0.84 | MAPK1 (0.69) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14506692 | 0.83 | MAPK1 (0.84) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4352530 | 0.83 | MAPK1 (0.73) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4357666 | 0.83 | MAPK1 (0.64) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14506687 | 0.83 | MAPK1 (0.82) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL9972524 | 0.82 | MAPK1 (0.67) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL5622692 | 0.82 | MAPK1 (0.64) | MAPK1PIK3CAMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130157976-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | CLAUS ECKHARD (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130157976-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | CLAUS ECKHARD (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130157976-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | CLAUS ECKHARD (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20120252760-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252760-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252760-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-8217042-B2 | Pyridopyrazines and their use as modulators of kinases | ZENTARIS GMBH (DE) | 2012-07-10 | — | — | US | disclosed |
| US-8217042-B2 | Pyridopyrazines and their use as modulators of kinases | ZENTARIS GMBH (DE) | 2012-07-10 | — | — | US | disclosed |
| US-8217042-B2 | Pyridopyrazines and their use as modulators of kinases | ZENTARIS GMBH (DE) | 2012-07-10 | — | — | US | disclosed |
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | MAPK1 47/4885PIK3CA 279/4885MAPK8 191/4885 |
| US-20120252760-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | MAPK1 47/4885PIK3CA 279/4885MAPK8 191/4885 |
| US-20130157976-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | MAPK1 47/4885PIK3CA 279/4885MAPK8 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.